Olesia Bissett

Télécommunications: discussions sur la Loi sur les Télécommunications (L.C. 1993, ch. 38) en ce qui concerne le cadre qui devrait guider le gouvernement dans l'éventualité d'une révision de la loi. Radiodiffusion: discussions sur la Loi sur la radiodiffusion (L.C.1991, c.11) en ce qui concerne le cadre qui devrait guider le gouvernement dans l'éventualité d'une révision de la loi. Politiques et réglementations en matière de spectre et de télécommunications, y compris les politiques et réglementations relatives aux interférences transfrontalières, aux réseaux sans fil 5G, aux interconnexions, à l'itinérance sans fil, à la mise aux enchères du spectre et aux stratégies économiques numériques Politiques et réglementations en matière de large bande, y compris les politiques et réglementations relatives au déploiement de la large bande en milieu rural, à la mesure des performances de l'internet, à la dynamique concurrentielle de la large bande, à la disponibilité de l'accès à l'internet en gros et à la disponibilité de l'internet à un prix abordable Impôts et Finances: Discussions sur le transfert intergénérationnel d'entreprise à contrôle familial Électrification des véhicules: Discussion avec les cabinets ministériels et les ministères au sujet de l’électrification de la flotte de véhicules de la compagnie Droit d'auteur: discussions sur la Loi sur le droit d'auteur (L.R.C. (1985), ch. C-42) en ce qui concerne le cadre qui devrait guider le gouvernement dans l'éventualité d'une révision de la loi.

Public health and prevention programs including the Public Health Agency of Canada and efforts to support the development and procurement of innovative vaccines and therapies to address major public health issues such as pandemic preparedness and RSV Federally-funded public drug plans, including the Non-Insured Health Benefits program, Canadian Armed Forces Drug Benefit List and veteran programs, with respect to reimbursement for drug products for beneficiaries Canada's Drug Agency policies and processes as it relates to reimbursement recommendation decision-making process and framework Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry Establish accountability with Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance, as well as Regulations, policies and programs related to the review and reimbursement processes Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada Annual federal Budgets and Budget updates relating to the biopharmaceutical industry. Scientific Research and Experimental Development (SR&ED) Tax Incentive Program regarding eligible expenditures. Discussions on policies such as "patent box" and Investment Tax Credits.

Arranging meetings to advocate for research and infrastructure support, and to increase awareness of the client's research capabilities.